| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 03/25/2004 | US20040059132 Reacting an indolin-2-one derivative with substituted benzyl halide to form substituted N-benzyl indolin-2-one derivatives have an affinity for oxytocin receptors |
| 03/25/2004 | US20040059130 Benz(f)indole compounds useful for Inflammatory Diseases |
| 03/25/2004 | US20040059113 Such as 3-(1-(2-hydroxyethyl)-1H-indol-3-yl)-4-(1-(3-pyridinyl)-1H-indol-3-yl)-1H -pyrrole-2,5-dione |
| 03/25/2004 | US20040059004 10-aryl-11h-benzo[b]fluorene derivatives and analogs for medicinal use |
| 03/25/2004 | US20040058987 Hypotensive agents; oxidation resistance, nitrogen scavenger; anticancer agents; antiischemic agents |
| 03/25/2004 | US20040058986 Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease |
| 03/25/2004 | US20040058981 Administering free radical generators such as artemisinim, arteflene |
| 03/25/2004 | US20040058980 Useful aroyl pyrrole heteroaryl methanones and methanols |
| 03/25/2004 | US20040058978 Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs |
| 03/25/2004 | US20040058972 Therapy for neovascularization; antitumor agents; vision defects; antidiabetic agents; antiarthritic agents |
| 03/25/2004 | US20040058969 React with tubulin; forming microtubes; stabilization; antitumor, anticancer agents; antiinflammatory agnets; psoriasis; antiarthritic agents |
| 03/25/2004 | US20040058964 Antiinflammatory agents; antiarthritic agents; antihistamines; sepsis shock; antidiabetic agents; bone disorders |
| 03/25/2004 | US20040058961 Antiallergens; antihistamines; autoimmune diseases; anticholesterol agents; cardiovascular diseases |
| 03/25/2004 | US20040058956 Oral absorption; bioavailability of antiproliferative agent |
| 03/25/2004 | US20040058940 Pharmaceutical formulation comprising thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2) |
| 03/25/2004 | US20040058939 Derivatives of variolin b |
| 03/25/2004 | US20040058932 Novel piperazine derivatives |
| 03/25/2004 | US20040058922 Tyrosine inhibitor; immunosuppressants; antiarthritic agents; autoimmune diseases; antiproliferative agent |
| 03/25/2004 | US20040058916 Central nervous system disorders; psychological disorders; schizophrenia; antiarthritic agents; Alzheimer's disease; anticancer agents |
| 03/25/2004 | US20040058915 Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists |
| 03/25/2004 | US20040058907 Compounds useful in the treatment of inflammatory diseases |
| 03/25/2004 | US20040058884 Detecting diseases by Selex method; anticancer agents |
| 03/25/2004 | US20040058869 Methods and reagents for modulating cholesterol levels |
| 03/25/2004 | US20040058866 Method for preparing tryptophan rich peptides |
| 03/25/2004 | US20040058394 Humanized anti-LT-beta-R antibodies |
| 03/25/2004 | US20040058363 Using presence of restriction fragment length polymorphism in udp-glucuronosyltransferase (UGT) gene to predict site effect reductions to irinotecan exposure |
| 03/25/2004 | US20040058358 Lipid metabolism transcription factor |
| 03/25/2004 | US20040058342 Comprises serine protease for diagnosis, prognosis and treatment of cell proliferative disorders |
| 03/25/2004 | US20040058338 Novel proteins and nucleic acids encoding same |
| 03/25/2004 | US20040058319 Comprises nucleotide sequences coding urogenital polypeptide for diagnosis and treatment cancer |
| 03/25/2004 | US20040058022 Method for producing fat and /or solids from beans and compositions containing polyphenols |
| 03/25/2004 | US20040058021 Which suppresses I-kappa-B-alpha phosphorylation through inhibition kinase activity and downregulating NF-kappa-B; antiproliferative agents |
| 03/25/2004 | US20040057992 6-phenyl-5-(4-(2-pyrrolidin-1-ylethoxy)phenyl)-5,6,7,8 -tetrahydronaphthalen-2-ol (laxofoxifene); a prodrug with a glidant, disintegrant, lubricant and diluent/filler in given amounts; unit dosage forms, including low dosage forms |
| 03/25/2004 | US20040057990 Liposomal benzoquinazoline thymidylate synthase inhibitor formulations |
| 03/25/2004 | US20040057964 Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from Uncaria tomentosa and related plants |
| 03/25/2004 | US20040057953 Modified peptides as therapeutic agents |
| 03/25/2004 | US20040057943 Probiotic strains, a process for the selection of them, compositions thereof, and their use |
| 03/25/2004 | US20040057934 Therapeutic agent for treating retroviral infection |
| 03/25/2004 | US20040057929 Administering viruses selected from modified adenovirus, modified HSV, modified vaccinia virus and modified parapoxvirus to mammal having Ras-activated pathway to result in lysis of proliferating cells |
| 03/25/2004 | DE10111682B4 Caloporosid-Derivate, Verfahren zu deren Herstellung und deren Verwendung Caloporoside derivatives, processes for their preparation and their use |
| 03/25/2004 | CA2502583A1 Isoquinoline derivatives having kinase inhibitory activity and medicament containing the same |
| 03/25/2004 | CA2499130A1 Methods for regulating cancer |
| 03/25/2004 | CA2498771A1 2',5'-oligoadenylate phosphodiesterase |
| 03/25/2004 | CA2498723A1 Design of chemokine analogs for the treatment of human diseases |
| 03/25/2004 | CA2498045A1 Compounds for modulating the glycolosis enzyme complex and/or transaminase complex |
| 03/25/2004 | CA2498004A1 Compositions and methods for the diagnosis and treatment of tumor |
| 03/25/2004 | CA2498000A1 Use of tumor-associated kinase (task) 110 antagonists for treating pancreatic cancers |
| 03/25/2004 | CA2497879A1 Use of a combination of dppe with other chemotherapeutic agents for the treatment of breast cancer |
| 03/25/2004 | CA2497801A1 Paks as modifiers of the chk pathway and methods of use |
| 03/25/2004 | CA2497793A1 Flj20647s as modifiers of the p21 pathway and methods of use |
| 03/25/2004 | CA2497790A1 Rors as modifiers of the p21 pathway and methods of use |
| 03/25/2004 | CA2497661A1 Compositions and methods for the diagnosis of immune related diseases using pro71061 |
| 03/25/2004 | CA2497182A1 Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor |
| 03/25/2004 | CA2497067A1 Amino-propanol derivatives |
| 03/25/2004 | CA2497025A1 Platinum complexes as antitumor agents in combination with biochemical modulation |
| 03/25/2004 | CA2497003A1 Inhibitors of factor xa and other serine proteases involved in the coagulation cascade |
| 03/25/2004 | CA2496764A1 Synthesis of indolizines |
| 03/25/2004 | CA2494274A1 Method and composition for regulating the activity of regulatory t cells |
| 03/25/2004 | CA2494216A1 Use of dendritic cells (dcs) expressing interleukin 12 (il-12) |
| 03/24/2004 | EP1400536A1 Method for making humanized antibodies |
| 03/24/2004 | EP1399744A2 Epf receptor assays, compounds and therapeutic compositions |
| 03/24/2004 | EP1399739A2 Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy |
| 03/24/2004 | EP1399593A2 Genes expressed in breast cancer as prognostic and therapeutic targets |
| 03/24/2004 | EP1399584A2 Cancer-linked genes as targets for chemotherapy |
| 03/24/2004 | EP1399578A2 Adsls as modifiers of the p53 pathway and methods of use |
| 03/24/2004 | EP1399570A2 Peptides for use as translocation factors |
| 03/24/2004 | EP1399565A2 Mitogenic oxygenase regulators |
| 03/24/2004 | EP1399554A2 Immunoglobulin superfamily proteins |
| 03/24/2004 | EP1399552A2 G-protein coupled receptor proteins (gpcr) and nucleic acids encoding same |
| 03/24/2004 | EP1399542A2 Methods for modulating gap junctions |
| 03/24/2004 | EP1399537A2 Therapeutic polypeptides, nucleic acids encoding same and methods of use |
| 03/24/2004 | EP1399483A2 Antibodies to insulin-like growth factor i receptor |
| 03/24/2004 | EP1399482A2 Determination of bone-sialoprotein in bodily fluids for oncological problems |
| 03/24/2004 | EP1399479A2 Cation conducting gaba a receptors and their use |
| 03/24/2004 | EP1399478A2 Cancer-testis antigens |
| 03/24/2004 | EP1399470A2 Dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents |
| 03/24/2004 | EP1399468A1 2-((n-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl)-amino)-alkylboronic acid derivatives |
| 03/24/2004 | EP1399462A1 Combined approach to treatment of cancer using a c-myc antisense oligomer |
| 03/24/2004 | EP1399455A2 Novel tricyclic dihydro-quinoline derivatives, method for preparing same and pharmaceutical compositions containing same |
| 03/24/2004 | EP1399449A1 Carbohydrate derivatives |
| 03/24/2004 | EP1399446A1 2,6,9-substituted purine derivatives and their use in the treatment of proliferative disorders |
| 03/24/2004 | EP1399441A1 N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| 03/24/2004 | EP1399440A1 5-(2-aminopyrimidin-4-yl)benzisoxazoles as protein kinase inhibitors |
| 03/24/2004 | EP1399439A1 2-heteroaryl-imidazotriazinones and their use in the treatment of inflammatory or immune diseases |
| 03/24/2004 | EP1399435A2 Pyridine derivatives useful as cd40:cd154 binding interruptors and use thereof to treat immunological complications |
| 03/24/2004 | EP1399433A2 Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 03/24/2004 | EP1399431A2 Novel nitriles useful as reversible inhibitors of cysteine proteases |
| 03/24/2004 | EP1399420A2 Pyrrolidines as dipeptidyl peptidase inhibitors |
| 03/24/2004 | EP1399411A1 Aloe-emodin derivatives and their use in the treatment of neoplastic pathologies |
| 03/24/2004 | EP1399406A2 Novel estrogen receptor ligands and methods i |
| 03/24/2004 | EP1399221A1 Compositions comprising oestrone-3-o-sulphamate and trail (tnf-related apoptosis inducing ligand) |
| 03/24/2004 | EP1399215A2 Tissue-specific endothelial membrane proteins |
| 03/24/2004 | EP1399188A2 Perylenequinones for use as photosensitizers and sonosensitizers |
| 03/24/2004 | EP1399185A2 Use of polyclonal immunoglobulins as vaccine |
| 03/24/2004 | EP1399179A2 Pharmaceutical compositions which inhibit proliferation of pituitary adenomas and method of use thereof |
| 03/24/2004 | EP1399175A2 Therapeutic use of rank antagonists |
| 03/24/2004 | EP1399168A1 Xenogenic oligoor/and polyribonucleotides as agents for the treatment of malignant tumours |
| 03/24/2004 | EP1399165A2 Stabilized dispersion of phytosterol in oil |
| 03/24/2004 | EP1399162A2 Treating neuropathic/inflammatory pain by targeting a composition (e.g. zd7288) to hcn pacemaker channels |
| 03/24/2004 | EP1399159A1 4-substituted-1-(arylmethylidene)thiosemicarbazide, 4-substituted-1-(arylcarbonyl)thiosemicarbazide and analogs as activators of caspases and inducers of apoptosis and the use thereof |